A University of Texas at Dallas researcher has received more than $1 million in grants from the Cancer Prevention & Research Institute of Texas (CPRIT) to develop treatments for solitary fibrous tumor, or SFT. The rare cancer develops when two genes, NAB2 and STAT6, become fused together, resulting in signals that initiate cancer-cell growth. The cause is unknown. While no medications have been developed specifically for SFT, treatment typically involves surgery to remove the tumor and/or radiation.

Researchers at the Indian Institute of Technology Gandhinagar (IITGN) have developed an antibiotic-free multifunctional injectable hydrogel that accelerates wound healing by simultaneously addressing oxidative stress, bacterial infection, and tissue regeneration. Featuring the first reported cerium–rutin nanocomplex for wound healing, the hydrogel demonstrated sustained therapeutic release, enhanced antioxidant and antibacterial activity, and faster wound closure in preclinical studies. Protected by a patent, the technology holds promise for both human and veterinary wound care and is available for clinical translation and industry partnerships.